Comprehensive tools that span the workflow, from research to the clinic.
Leverage magnetic beads and reagents: trusted solutions for sample collection and T-cell isolation.
Catalog Number 4924948
Catalog Number 7159234
Catalog Number 10723874
Find tools and reagents needed for T-cell engineering and manipulation.
Catalog Number 17118715
Catalog Number 12313563
Catalog Number 10090314
Benefit from trusted products for cell culture, activation and expansion of T-cells including media, reagents and equipment.
Catalog Number 5232748
Catalog Number 4524963
Catalog Number 10084450
Explore reliable and high-quality solutions for cell analysis and cryopreservation.
Catalog Number 11560446
Catalog Number 15813915
Catalog Number 3111871
Discover scalable solutions for advancing cell therapy process.
22_04.jpg-650.jpg)
Catalog Number 17775079
Complete your order with safety products.
Catalog Number 15614987
Catalog Number 15547171
Catalog Number 11726713
CAR T-cell therapy is an innovative development in the field of oncology, particularly for patients with late-stage or rare forms of cancer. We offer products and tools to help researchers and manufacturers develop cell therapies. Here you find solutions that support you across the entire workflow, from T-cell isolation and activation to cell engineering and expansion, including scalable solutions to help get you from basic research to the clinic.
Chimeric antigen receptor T-cells (CAR T-cells) are made from a patient's T-cells that are harvested through apheresis and genetically modified in a laboratory to express a chimeric antigen receptor. When the CAR T-cells are reinjected into the patient's body, they target cell-surface antigens expressed on tumour cells and eliminate cancer cells throughout the body.
CAR T therapy has been shown to achieve complete remission in patients with liquid cancers like B-cell malignancies. However, CAR T therapy has not had similar success targeting solid tumours. Solid cancerous masses are often hypoxic, acidic, and immunosuppressive, making it difficult for T-cells to infiltrate and survive in that environment.
The main challenges of CAR T-cell manufacturing include supply constraints, scalability, and storage issues.
Autologous CAR T-cell therapies use a patient's own immune cells while allogeneic, or off-the-shelf, CAR T-cell products derive from healthy blood donors. Autologous CAR T-cells make up most clinically proven CAR cell products and are part of the standard of care for multiple blood diseases. Despite its effectiveness this strategy has several limitations in terms of costs and logistics that could be overcome by allogeneic CAR T-cell therapy. Many companies and start-ups were focussing on allogeneic CAR T therapies, as allogeneic immunotherapies were seen as the next big thing in cell therapies. However, allogeneic CAR cell products come with their own challenges, including the potential to induce graft-versus-host-disease and other uncertainties like chromosomal abnormality.
All of the FDA-approved CAR T-cell therapies rely on a disarmed virus to generate CAR T-cells. However, dealing with virus-derived vectors brings potential obstacles in the CAR T-cell manufacturing process due to strict regulations, speed of manufacturing, toxicities and high costs. To overcome these hurdles, currently several research teams have used gene-editing technologies like TALON and CRISPR to induce the donated T-cells to produce CARs.
